scholarly journals Linkage Analysis of Extended High-Risk Pedigrees Replicates a Cutaneous Malignant Melanoma Predisposition Locus on Chromosome 9q21

2013 ◽  
Vol 133 (1) ◽  
pp. 128-134 ◽  
Author(s):  
Lisa A. Cannon-Albright ◽  
Craig C. Teerlink ◽  
James M. Farnham ◽  
Alun W. Thomas ◽  
John J. Zone ◽  
...  
Keyword(s):  
High Risk ◽  
Malignant Melanoma ◽  
Linkage Analysis ◽  
Cutaneous Malignant Melanoma

Large deletions of chromosome 9p in cutaneous malignant melanoma identify patients with a high risk of developing metastases

2000 ◽  
Vol 10 (3) ◽  
pp. 231-236 ◽  
Author(s):  
S. Puig ◽  
J. Castro ◽  
P. J. Ventura ◽  
A. Ruiz ◽  
C. Ascaso ◽  
...  
Keyword(s):  
High Risk ◽  
Malignant Melanoma ◽  
Cutaneous Malignant Melanoma ◽  
Large Deletions ◽  
Chromosome 9P

Large deletions of chromosome 9p in cutaneous malignant melanoma identify patients with a high risk of developing metastases

2000 ◽  
Vol 10 (3) ◽  
pp. 231-236 ◽  
Author(s):  
S. Puig ◽  
J. Castro ◽  
P. J. Ventura ◽  
A. Ruiz ◽  
C. Ascaso ◽  
...  
Keyword(s):  
High Risk ◽  
Malignant Melanoma ◽  
Cutaneous Malignant Melanoma ◽  
Large Deletions ◽  
Chromosome 9P

scholarly journals TRIM study protocol - a prospective randomized multicenter Trial to assess the Role of Imaging during follow-up after radical surgery of stage IIB-C and III cutaneous malignant Melanoma

BMC Cancer ◽  
2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Ylva Naeser ◽  
Hildur Helgadottir ◽  
Yvonne Brandberg ◽  
Johan Hansson ◽  
Roger Olofsson Bagge ◽  
...  
Keyword(s):  
Quality Of Life ◽  
High Risk ◽  
Malignant Melanoma ◽  
Potential Benefit ◽  
Radical Surgery ◽  
Multicenter Trial ◽  
Cutaneous Malignant Melanoma ◽  
Link Type

Abstract Background The incidence of cutaneous malignant melanoma (CMM) is increasing worldwide. In Sweden, over 4600 cases were diagnosed in 2018. The prognosis after radical surgery varies considerably with tumor stage. In recent years, new treatment options have become available for metastatic CMM. Early onset of treatment seems to improve outcome, which suggests that early detection of recurrent disease should be beneficial. Consequently, in several countries imaging is a part of the routine follow-up program after surgery of high risk CMM. However, imaging has drawbacks, including resources required (costs, personnel, equipment) and the radiation exposure. Furthermore, many patients experience anxiety in waiting for the imaging results and investigations of irrelevant findings is another factor that also could cause worry and lead to decreased quality of life. Hence, the impact of imaging in this setting is important to address and no randomized study has previously been conducted. The Swedish national guidelines stipulate follow-up for 3 years by clinical examinations only. Methods The TRIM study is a prospective randomized multicenter trial evaluating the potential benefit of imaging and blood tests during follow-up after radical surgery for high-risk CMM, compared to clinical examinations only. Primary endpoint is overall survival (OS) at 5 years. Secondary endpoints are survival from diagnosis of relapse and health-related quality of life (HRQoL). Eligible for inclusion are patients radically operated for CMM stage IIB-C or III with sufficient renal function for iv contrast-enhanced CT and who are expected to be fit for treatment in case of recurrence. The planned number of patients is > 1300. Patients are randomized to clinical examinations for 3 years +/− whole-body imaging with CT or FDG-PET/CT and laboratory tests including S100B protein and LDH. This academic study is supported by the Swedish Melanoma Study Group. Discussion This is the first randomized prospective trial on the potential benefit of imaging as a part of the follow-up scheme after radical surgery for high-risk CMM. Results The first patient was recruited in June 2017 and as of April 2020, almost 500 patients had been included at 19 centers in Sweden. Trial registration ClinicalTrials.gov, NCT 03116412. Registered 17 April 2017, https://clinicaltrials.gov/ct2/show/study/NCT03116412

Recombinant Human Interferon γ: Adverse Effects in High-risk Stage I and II Cutaneous Malignant Melanoma

1990 ◽  
Vol 82 (12) ◽  
pp. 1071-1071 ◽  
Author(s):  
FRANK L. MEYSKENS ◽  
KENNETH KOPECKY ◽  
MICHAEL SAMSON ◽  
EVAN HERSH ◽  
JOHN MACDONALD ◽  
...  
Keyword(s):  
High Risk ◽  
Malignant Melanoma ◽  
Adverse Effects ◽  
Interferon Γ ◽  
Cutaneous Malignant Melanoma ◽  
Stage I ◽  
Human Interferon
Sign in / Sign up

Export Citation Format

Share Document